Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide

Clinical Pharmacology and Therapeutics

Volumn 69, Issue 6, 2001, Pages 400-406

  Niemi, M ^a   Backman, J T ^a   Neuvonen, M ^a   Neuvonen, P J ^a   Kivisto K T ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; GLIBENCLAMIDE; GLIPIZIDE; GLYCOPROTEIN P; MINDIAB; PLACEBO; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME INDUCTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIBIOTICS, ANTITUBERCULAR; AREA UNDER CURVE; BLOOD GLUCOSE; FEMALE; GLIPIZIDE; GLYBURIDE; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; RIFAMPIN;

EID: 0034979614     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.115822     Document Type: Article

References (36)

1. Bioavailability, pharmacokinetics and effects of glipizide in type 2 diabetics
2. Comparison of the kinetics of glyburide and its active metabolites in humans
3. The metabolism of glyburide in subjects of known debrisoquin phenotype
4. Concentration-effect relations of glibenclamide and its active metabolites in man: Modelling of pharmacokinetics and pharmacodynamics
5. Glipizide: An oral hypoglycemic drug
6. Hypoglycemic agents
7. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele
8. 14C-glyburide in patients with varying renal function
9. Pharmacokinetics and pharmacodynamics of glipizide in healthy volunteers
10. Pharmacokinetic drug interactions with rifampicin
11. The mechanism of the warfarin-rifampin drug interaction in humans
12. Enzyme induction in the elderly: Effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone
13. In vivo modulation of CYP enzymes by quinidine and rifampin
14. Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9
15. Effect of tuberculostatic agents on the response of serum growth hormone and immunoreactive insulin to intravenous tolbutamide, and on the half-life of tolbutamide
16. Drug interaction: Rifampicin and glibenclamide
17. Interaction of rifampin and glyburide
18. P-glycoprotein inhibition by glibenclamide and related compounds
19. Effect of oral verapamil on glibenclamide stimulated insulin secretion
20. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
21. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction
22. Glimepiride: A review of its use in the management of type 2 diabetes mellitus
23. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride
24. Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus
25. Rifampin decreases the plasma concentrations and effects of repaglinide
26. Rifampin drastically reduces plasma concentrations and effects of oral midazolam
27. Triazolam is ineffective in patients taking rifampin
28. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations
29. Concentrations and effects of buspirone are considerably reduced by rifampicin
30. Characterization of human small intestinal cytochromes P-450
31. Quantitative analysis of constitutive and inducible CYPs mRNA expression in the HepG2 cell line using reverse transcription-competitive PCR
32. A mechanistic approach to antiepileptic drug interactions
33. St John's wort: Effect on CYP3A4 activity
34. St John's wort induces hepatic drug metabolism through activation of the pregnane X receptor
35. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4
36. Safety of St John's wort